David Scott Moore bought $250K of Corvus Pharmaceuticals (CRVS)
Executed Jun 11, disclosed Jun 15, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Jun 15), the stock returned +24.2% (delay-adjusted); from the execution session (Jun 11), +31.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
David Scott Moore (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Corvus Pharmaceuticals, Inc. (CRVS). Across 1 priced purchase filing, the average 21-session return was +31.6% from execution and +24.2% from disclosure (delay-adjusted; derived). The largest single filing was $250K of CRVS (21,700 sh × $11.53, as filed), executed Jun 11.
Healthcare · Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely t…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→